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AntihypertensiveThis article aims to discuss differences in pharmacological treatment through a period of 10 years from 2003 to
2013. Hypertension treatment faces many challenges because of patients' unawareness and adherence, clinical
inertia, as well as rapid availability of new medical literature and trials. Since 2003, JNC 7 was published at nearly
the same timewith ESC/ESHGuidelines andWHO/ISH Statement onmanagement of hypertension [1–3]. However,
these guidelines are not homogenous in pharmacological therapy approach. Moreover, during the 10 years since
2003, many new large trials, data, and updated guidelines have resolved some main controversial problems in
blood pressure (BP) goals in separate risk-categorized patients, levels of BP for initial antihypertensive therapy,
choice of drugs in monotherapy, indication for drug combinations, and preferred combinations for special cases.
The latest updated guidelines on hypertension treatment, 2013 ESC/ESH Guidelines for the management of
arterial hypertension, not only contain signiﬁcant changes in the abovementioned problems, but also raise some
new questions for the future research [4].
© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Blood pressure classiﬁcations
In 2003, some important observational studies were acknowledged
and considered as key data for the JNC 7 new blood pressure classiﬁca-
tion (Table 1) [1]. Indeed, the “normal” BP range in the JNC 6 or other
previous guidelines was not proved to be normal [5]. A meta-analysis
of one million adults from 61 prospective studies demonstrated that
mortality rate of ischemic heart disease (IHD) and stroke linearly rose
when the SBP values above 115 mm Hg and DBP values greater than
75 mm Hg were observed [6]. This ﬁnding was also conﬁrmed by the
Framingham Heart Study, in which individuals with BP values between
130–139/85–90 mm Hg had two-times higher cardiovascular disease
(CVD) relative risk in comparison with one whose BP values were
below 120/80 mm Hg [7]. In addition, in a WHO report, the previously
deﬁned suboptimal BP (SBP N 115 mm Hg) range was linked with 62%
of cerebrovascular disease and 49% of IHD [8]. According to this data,
the deﬁnition of “prehypertension”, which was not considered as a dis-
ease category, was mentioned for the ﬁrst time in JNC 7 with the claim
that the earlier the control of BP by healthy lifestyle, the greater reduc-
tion in BP values as well as the slower the progression of hypertension
[1]. Also, in JNC 7, Stage 3 hypertension was no longer used since ity, University of Missouri, 125
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).
land Ltd. Open access under CC BY-NCand Stage 2 hypertension had similar management strategies [1]. New
JNC has not been published yet, and JNC 7 is still the most widely used
classiﬁcation in hypertension management [1].
However, the 2003 ESC/ESH Guidelines as well as the 2003 WHO/
ISH Statement on management of hypertension did not share JNC 7's
view, since they indicated that the term “prehypertension” could be
confusing andmight detract attention from investigation of themecha-
nisms raising BP and diminish the case for tight BP control [1–3]. So,
during the ten year period since JNC 7's publication, in the ESC/ESH
Guidelines of management arterial hypertension published in 2007,
2009, and even in 2013, no change in classiﬁcation has been made
(Table 2) [4,9,10].2. Blood pressure goals
In ten years, many conﬂicting results from observational studies and
randomized-controlled trials have affected the BP goals for hyper-
tensive patients with and without compelling indication treatment
(Table 3).
In the year 2003, data on target BP corresponding to BP classiﬁca-
tions and speciﬁc indications are rare, and more evidence was available
for DBP than for SBP. With the exception of the subgroup of the HOT
trial, in which reduction of DBP values to below 90 mm Hg in non-
diabetes was not associated with signiﬁcant advantage in outcome
[16], most of the other studies were related to diabetes, such as:
UKPDS [17], ABCD-NT [18], ABCD-HT [19], and MICROHOPE trials [20].
In HOT [16], UKPDS [17], and MICROHOPE trials [20], the DBP values-ND license.
Table 2
ESC/ESH classiﬁcation of BP levels.
Blood pressure classiﬁcation SBP (mm Hg) DBP (mm Hg)
Optimal b120 b80
Normal 120–129 80–84
High normal 130–139 85–89
Grade 1 hypertension (mild) 140–159 90–99
Grade 2 hypertension (moderate) 160–179 100–109
Grade 3 hypertension (severe) ≥180 ≥110
Isolated systolic hypertension ≥140 b90
SBP: systolic blood pressure; DBP: diastolic blood pressure.
2 T.M. Tran, N.M. Giang / IJC Metabolic & Endocrine 2 (2014) 1–10between 77 and 82mmHg could be achieved and associated with ben-
eﬁt. In addition, the SBP values in these 3 trials could not be lowered
below 140 mm Hg. ABCD-NT [18] and ABCD-HT [19], at that time,
were the only two trials in diabetes that had achieved SBP values
below 140 mm Hg, but the only signiﬁcant reduction in total mortality
was obtained by ABCD-HT [19] in much the same way as reduction in
stroke seen in ABCD-NT [18]. On the other hand, in other special condi-
tions, SBP values obtained in the intensive treatment groups of some tri-
als favored outcome beneﬁts, but SBP values below 140 mm Hg were
rarely achieved. For example, the average SBPs of 138, 144, and
140 mm Hg were achieved in the PROGRESS trial [21] with previous
stroke and TIA patients, the PATS trial [22] with post-stroke patients,
and the HOPE trial [23] with high risk CVD patients respectively. In
CKD patients, conﬂicting data was obtained about the beneﬁt of lower-
ing SBP to below 140 mm Hg [24–26]. So, JNC 7 recommendations [1]
and the 2003 ESC/ESH guidelines [2] were similar in target BP, except
for the case of CKD and initial therapy for high-normal range BP in
high and very high risk individuals.
Later, in the year 2007–2008, with the publication of new large ran-
domized trials, ESC/ESH [9] and AHA [12] shared the same view that the
target BP below 130/80 should also be used for high risk and very high
risk patients. In these studies, a lower BP target in comparison with
values in previous major recommendations favored beneﬁts in CVD
outcome, such as the CAMELOT trial (BP of 124/76 mm Hg better than
130/77 mm Hg) [27], and the EUROPA trial (128/78 mm Hg rather
than 133/80 mm Hg) [28]. Therefore, it was reasonable to consider the
target BP of below 130/80 to be more suitable for high risk and very
high-risk patients.
Until 2009, continuously updated information led to new
changes in treatment strategy. During a long time, pharmacological
treatment was recommended for high risk patients with high nor-
mal BP range in ESC/ESH guidelines [10], but evidence supporting
this view was scant. In most studies, clear-cut beneﬁts of BP-
lowering drugs were seen only when initial SBP was higher than
140 mm Hg. In low-to-moderate risk patients, the beneﬁt of BP-
lowering therapy was almost consistently seen in individuals
with initial SBP ≥ 160 mm Hg (recommended in CHEP Guidelines)
[13,15]. In coronary high risk patients, the HOPE [23], CAMELOT
[27], EUROPA [28], PEACE [29], ACCESS [30], and PROFESS trials
[31] could not prove the persistent beneﬁt when the obtained
BP was below 130/80 as well as the advantage of high BP range
treatment, except for the EUROPA [28] and CAMELOT trials [27].
Moreover, few trials seem to approve the goal of a BP of b130/
80 mm Hg for diabetes patients. In many trials in hypertensive
diabetic patients (HOT [16], SHEP [32], UKPDS [17], Syst-Eur [33],
ABCD [34], ADVANCE [35], and PROGRESS [21] trials), only the
ABCD-NT [18] trial achieved BP below 130/80 mm Hg (average
BP value of 128/75 mm Hg); however, the CV outcome beneﬁt
was not signiﬁcant. Recently, a similar ﬁnding was seen in the
ACCORD trial (2010), which cannot indicate a signiﬁcant reduction
in incidence of major CV events between those whose SBP lowered
to an average of 119 mm Hg and those whose SBP remained at an
average of 133 mm Hg [36]. In addition, the DBP values between
77 and 82 mm Hg were proved to be safe and beneﬁcial in theTable 1
JNC 7 classiﬁcation of BP for adults.
Blood pressure classiﬁcation SBP (mm Hg) DBP (mm Hg)
Normal b120 and b80
Prehypertension 120–139 or 80–89
Stage 1 140–159 or 90–99
Stage 2 ≥160 or ≥100
SBP: systolic blood pressure; DBP: diastolic blood pressure.HOT [16], UKPDS [17], and MICROHOPE trials [20]. So, in the new
ESC/ESH Guidelines in 2013 [4], the BP target for diabetes mellitus
patients is recommended to be below 140/85 mm Hg (Class I,
Level A).
For the elderly, the HYVET study [37] has been considered the key
data for hypertension management. Before this trial (2008), most of
the major hypertension guidelines had had the same target BP for all
patients, regardless of age, and few studies mentioned the octogenar-
ians. In the HYVET [37], all of these individuals were older than 80
with the initial SBP ≥ 160 mm Hg, the lowering of BP to the average
value of 144/78 mm Hg was associated with a signiﬁcant reduction in
all-causemortality as well as the incidence of stroke, CHF, CVmorbidity,
and fatal events.
3. Monotherapy versus combination therapy
In 2002, ALLHAT — the largest hypertension clinical trial ever
conducted which contributed major data for JNC 7, indicated that
only about one third of the patients achieved the target BP (b140/
90 mmHg) induced by antihypertensive monotherapy [41]. Moreover,
the HOT [16], CONVINCE [38], and LIFE trials [39] also had this similar
ﬁnding. So, JNC 7 [1] recommended initiating antihypertensive treat-
ment in Stage 1 hypertension with monotherapy, and when BP was
not well controlled by single drug usage (that is BP N 20 mm Hg
above systolic goal and N10 mm Hg above diastolic goal), combination
therapy should be initiated. In Stage 2 hypertension as well as in some
compelling indications (diabetes mellitus, IHD, CKD, stroke and HF),
beginning antihypertensive treatment with drug combinations was
also recommended since this therapywas themost popular one in trials
related to these high risk patients. Again, ESC/ESH 2003 [4] and BHS
2004 [11] shared somewhat similar views, although their recommenda-
tions were not as detailed as JNC 7's [1].
In the later edition of ESC/ESH Guidelines [4,9,10] on hypertension,
results suggested initiating monotherapy only in mild BP elevation
with low or moderate total CV risk, and beginning combination treat-
ment of two drugs at low doses for Grade 2 and Grade 3 hypertensive
individuals or mild BP elevation patients with high or very high risk
(target organ damage, diabetes, renal disease, or a history of CVD).
Finally, the similar recommendations of combination antihyperten-
sive treatment have been again reconﬁrmed in later updated Guidelines
of AHA and ACC in 2007 [12] and 2011 [14] as well as in CHEP 2012 and
2013 [15], and in ESC/ESH Guidelines 2009 [10] and 2013 [4] with the
important data taken from a meta-analysis of 42 trials. In these trials,
the combination of two agents from any different classes of antihyper-
tensive drugs not only induces better BP control than the increase in
the dose of current-use agent, but also limits the adverse side effects
of high-dose single antihypertensive treatment [40].
3.1. Choice of drugs as monotherapy in hypertensive treatment
Based mainly on the ALLHAT trial [41] as well as the availability
and cost of drugs, JNC 7 Guidelines [1], 2003 WHO/ISH Statement
Table 3
Comparison of BP goals recommended in Antihypertensive Guidelines.
Sponsoring organizations (year) Patient assessment Target SBP/DBP (mm Hg)
JNC 7 (2003) [1] All patients except for diabetes mellitus and CKD Stage 1 and Stage 2 hypertension b140/90
Speciﬁc disease indication Diabetes mellitus b130/80
CKD b130/80
ESC/ESH Guidelines for Management of
Hypertension (2003) [2]
No compelling indication High normal BP: very high risk, high risk b140/90
Grade 1, 2 and 3 hypertension b140/90
Speciﬁc disease indication Diabetes mellitus b130/80
BHS Guidelines for Management of
Hypertension (2004) [11]
No compelling indication Grade 1 with CVD, target organ damage, CVD risk ≥ 20% (JBS risk chart) b140/85
Grade 2, 3 hypertension b140/85
Speciﬁc disease indication Diabetes mellitus (above Grade 1 hypertension) b130/80
AHA & ACC Treatment of Hypertension in
the Prevention and Management of Ischemic
Heart Disease (2007) [12]
Primary prevention in high risk coronary artery
disease patients
Diabetes mellitus, CKD, CAD, CAD risk equivalent, carotid artery disease, PAD
abdominal aortic aneurysm, Framingham risk score ≥ 10%
b130/80
LVD b120/80
Other patients None of the above, Stage 1 and Stage 2 hypertension b140/90
ESC/ESH Guidelines for management of
hypertension (2007) [9]
No compelling indication High normal BP: very high risk, high risk b140/90
Grade 1 and Grade 2: with high or very high cardiovascular risk Grade 3 b140/90
Compelling disease indication Diabetes mellitus b130/80
Very high or high risk (stroke, MI, renal dysfunction, proteinuria) b130/80
Canadian Hypertension Education
Program-CHEP (2009) [13]
No compelling indication Patients without macrovascular target organ damage and other
cardiovascular risk factors: BP ≥ 160/100 mm Hg
Patients with macrovascular target organ damage and other
cardiovascular risk factor: BP ≥ 140/90 mm Hg
b140/90
Compelling indication Diabetes mellitus b130/80
CKD b130/80
CAD, LVD, stroke or TIA b140/90
ESC/ESH Guidelines for management of
hypertension (2009) [10]
No compelling indication High normal BP without diabetes mellitus and previous
cardiovascular events
No trial evidence associated with beneﬁt
Grade 1 with high risk
Grade 2 and grade 3
b140/90
(130–139/80–85)
Compelling indication Diabetes mellitus with BP ≥ 140/90 mm Hg 130–139/80–85
CKD, CVD with BP ≥ 140/90 mm Hg 130–139/80–85
ACCF/AHA Expert Consensus Document on
Hypertension in the Elderly (2011) [14]
No compelling indication Stage 1 and Stage 2 Target SBP ≤ 140 for patients N55 years old. For
those aged ≥80, 140 to 145, if tolerated.Compelling indication HF, post MI, CAD, high cardiovascular risk, angina pectoris,
aortic aneurysm, diabetes, CKD, stroke
Canadian Hypertension Education Program —
CHEP (2013) [15]
No compelling indication Patients without macrovascular target organ damage and
other cardiovascular risk factors: BP ≥ 160/100 mm Hg
Patients with macrovascular target organ damage and
other cardiovascular risk factor: BP ≥ 140/90 mm Hg
b140/90
Compelling indication Diabetes mellitus b130/80
CKD b140/90
CAD, LVD, stroke or TIA b140/90
ESC/ESH Guidelines for management of
hypertension (2013) [4]
No compelling indication Grade 1 with high risk
Grade 2 and Grade 3
b140/90
Grade 2 and Grade 3 in elderly 140–150/90
Compelling indication Diabetes mellitus b140/85
Previous stroke, TIA, CHD, CKD b140/90
ACC: American College of Cardiology; AHA: American Heart Association; BP: blood pressure; BHS: British Hypertension Society; CAD: coronary artery disease; CKD: chronic kidney disease; DBP: diastolic blood pressure; ESC: European Society of
Cardiology; ESH: European Society of Hypertension;HF: heart failure; JBS: Joint British Societies; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LVD: left ventricular
















4 T.M. Tran, N.M. Giang / IJC Metabolic & Endocrine 2 (2014) 1–10[3], and 2004 BHS Guidelines [11] considered thiazide-type diuretics
as the ﬁrst-line treatment for most patients in monotherapy or a
combination with one of other classes. In contrast, 2003 ESC/ESH
Guidelines mentioned that one of ﬁve major classes of antihyperten-
sive agents (diuretics Ds, beta-blockers BBs, calcium antagonists CAs,
angiotensin-converting enzyme inhibitors ACEIs, angiotensin receptor
blockers ARBs) could be used appropriately as initiation andmaintenance
therapy in hypertensive individuals, since important beneﬁts of antihy-
pertensive treatment came fromthe level of BP lowering itself andexisted
independently from the drugs used in uncomplicated hypertension
[2]. This conclusion was proved by a number of large randomized tri-
als (CAPP [42], STOP-HT2 [43], NORDIL [44], UKPDS [17], and
INSIGHT trials [45]) in which at the same level of BP control, most
antihypertensive treatments induce the same degree of CV protection.
In addition, BHS Guidelines 2004, based on the theory of “low renin” (in
individualsN55 years andblack population) and “high renin” (in younger
people b55 years and Caucasians) hypertension, recommended CA or D
as the ﬁrst-line therapy in low renin population and ACEI/ARB or BB as
the initial treatment for high renin individuals [11].
Nevertheless, later updated guidelines from major organizations in
2007 and 2009 share more homogenous views about this problem.
While 2007 [9], 2009 [10], and 2013 ESC/ESH Guidelines [4], and annual
CHEP Guidelines [13,15] have re-conﬁrmed their previous recommen-
dations of ﬁrst-line treatment using the ﬁve classes of drug mentioned
above, 2007 AHA/ACC Guidelines of Prevention and Management of
IHD indicated that most evidence supported the use of four classes
(ACE-I; ARB; CA or thiazide-type diuretics as ﬁrst-line therapy); and
BBs which were favored in post MI, angina pectoris, as well as beta1-
selective agents in acute MI [12]. NICE Guidelines in 2011 [46] and
2013 [47] have also omitted BB for ﬁrst-line therapy for patients
under 55 years old.
3.1.1. Diuretics
During the ten years since 2003, therewas big change in the position
of diuretics in hypertensive treatment approach. ALLHAT [41]— a direct
comparison trial, and many previous large trials [48–50] in which
thiazide-type diuretics were the basic therapy proved that these agents
in comparison with other classes were superior in prevention of one or
more major outcomes of CVD and are less expensive. In addition, in a
network meta-analysis in 2003 of 42 clinical trials, low-dose diuretics
were superior to placebo in: CHD, CHF, stroke, CVD events, CVDmortal-
ity, total mortality, and none of the other ﬁrst-line treatment strategies
– BBs, ACEIs, CAs, α-blockers, and ARBs – was signiﬁcantly better than
low-dose diuretics for any outcome [51]. More recently, in Cochrane
meta-analysis 2009, ﬁrst-line thiazide treatment was associated with a
signiﬁcant reduction in mortality, stroke, CHD, and total cardiovascular
events; however, in comparison with high-dose treatment, low-dose
thiazide therapy had more consistent beneﬁts [52].
Nevertheless, also in theALLHAT trial, adverse effects induced by thi-
azide treatment, including hypokalemia, hyperglycemia, and especially
new-onset of diabetes mellitus, were higher than other agents [41].
Moreover, 2004 BHS recommendations [11], 2007 ESC/ESH Guidelines
[9], and Elliott and Meyer meta-analysis [53] of 22 clinical trials
approved that thiazide-type diureticswere linkedwith higher incidence
of new-onset diabetes mellitus, especially in combination with BB in
patients withmetabolic syndrome or with high risk of incidental diabe-
tes. So, with their positive points and negative points, it is not reason-
able to prefer diuretics to other agents for initial therapy anymore.
3.1.2. Beta blockers
In comparison between BBs and placebo or no treatment, a meta-
analysis in 1997 indicated that BBs therapy induced reduction in stroke
and CHF (but not in CHD) [50]. However, a Cochrane systemic review in
2012 showed that BB ﬁrst-line therapy caused beneﬁts in lowering total
cardiovascular disease but no advantage was seen in total mortality
[55].In comparison between BBs and other classes of antihypertensive
drugs, conﬂicting data was obtained. A meta-analysis in 2005 found
that initial BB treatment was inferior to other agents in stroke preven-
tion, but no difference was seen in MI [56]. Moreover, another very
largemeta-analysis of 147 randomized trials showed that BBwas better
than other drugs in patients after MI, was slightly inferior in preventing
stroke, and no difference was found in preventing CAD events or HF
[57]. A somewhat similar ﬁnding was obtained in Cochrane meta-
analysis in which BBs were inferior only to CAs in total mortality and
CV events, was inferior to CAs, ACEIs or ARBs in stroke, and had the
same beneﬁts as other agents in CHD [55]. Nevertheless, a meta-
analysis in 2006 of 21 trials (with ASCOT and CONVINCE comprising
the majority of all participants) found that the increased risk of stroke
with BB was limited in patients ≥60 years of age [58].
However, BBs are a heterogeneous group with various mechanisms
in hypertension pathology. Most trials comparing BBs and other antihy-
pertensive drugs in primary hypertension used the old BB (with ateno-
lol used for the most part). Some new BBs, such as carvedilol, nebivolol
and celiprolol with a vasodilating characteristic, have a better effect on
central pulse pressure reduction as well as aortic stiffness than meto-
prolol or atenolol [59]; these new BBs were considered to have less of
an effect on insulin resistance [60]. In addition,metoprolol and carvedil-
ol have been the popular agents used in clinical trials in which patients
had existing CAD, and have induced persistent beneﬁts in this type of
patient by many meta-analysis trials [57,61,62].
With this conﬂicting data, both ESC/ESH guidelines [2,4,9,10] and
CHEP recommendations [13,15] considered BBs as another kind of ini-
tial therapy antihypertensive drugs, but this view has not been shared
by ACC/AHA Guidelines [12], which favored BB in patients linking
with CAD history only.
3.1.3. Calcium antagonist
Some randomized trials comparing initial CA treatment with place-
bo or no treatment (STONE [63], Syst-China [64] and Syst-Eur [33])
mostly conﬁrmed the signiﬁcant beneﬁt of CAs in stroke, all cause
mortality and CVD outcome.
Trials provided important results about CAs, rather than Ds, BBs,
ACEIs or ARBs. In ALLHAT trials, amlodipine and chlorthalidone had no
statistical difference in all category outcomes, except HF [41]. In 2010,
in a Cochrane meta-analysis of 18 RCTs (AASK, ABCD, ALLHAT, ASCOT-
BPLA, CONVINCE, ELSA, FACET, IDNT, INSIGHT, INVEST, MIDAS, NICS-
EH, NORDIL, SHELL, STOP-Hypertension-2, TOMHS, VALUE and VHAS),
CA had no signiﬁcant difference from other agents in total mortality,
but they had lower incidence of MI than ARBs, lower risk of stroke
than ACEIs or ARBs, lower total cardiovascular events than BBs, and
had higher CHF risk than Ds, ACEIs, ARBs [65]. In another very large
meta-analysis of 147 randomized trials, when compared with Ds, BBs,
and ACEIs, CAs were inferior by 20% in incidence of new-onset HF
[60]. However, like BBs, CAs are not a homogenous group, with
amlodipine considered as safe and beneﬁcial in HF treatment.
3.1.4. ACE-I
In trials comparing ACEI based treatment with placebo (including:
HOPE [23], PART-2 [66], QUIET [67], SCAT [68] and EUROPA trials [28])
withmost participants having either coronary disease or CVD, statistical
advantageswere seen in CV death,major CV events, HF, CHDand stroke.
The same results were found in a Cochrane meta-analysis in 2009 [52]
and another one in 2012[54].
However, there is not enough evidence to adopt ACEI initial treat-
ment over other drugs. In CAPP trial, no beneﬁt was found when com-
paring captopril with BBs and/or Ds in CV events [42]. However, the
ANBP2 trial directly compared outcomes with an ACEI (enalapril) and
a D (hydrochlorothiazide) in hypertensive elderly people (aged 65 to
84 years old), the results of which indicated that the ACEI group had
better effects on the primary endpoints such as all-cause mortality or
CV events, but these effects were limited in men [69]. According to a
5T.M. Tran, N.M. Giang / IJC Metabolic & Endocrine 2 (2014) 1–10meta-analysis of three studies (ALLHAT, JMIC-B and STOP-H2) compar-
ing ACEIwith CA, ACEIswere associatedwith higher incidence of stroke,
but lower incidence of new-onset diabetes and HF [46]. Although both
ACEIs and ARBs belong to the renin–angiotensin-system blockage,
they produced different trial results. ARBs seem to be less effective
than ACE-I in MI prevention [70] as well as in all-cause mortality [54].
However, in the last ONTARGET trial that compared ACE-I (ramipril)
with ARB (telmisartan) in high-risk patients, no differencewas detected
in major cardiac outcome, stroke, all-cause mortality and especially in
new-onset diabetes [71].
ACE-I has an undeniable role in delaying the progression of kidney
disease as well as proteinuria, and this ﬁnding was proved by several
trials [26,39,72,73].
3.1.5. ARB
In trials comparing ARBwith placebo, identical data was not obtain-
ed. In the PROFESS trial, adding telmisartan did not the improve out-
come in recurrent stroke or major CV events in comparison with
placebo [31]. In the SCOPE trial [74], candesartan induced non-
signiﬁcant reduction in major CV events, and all-cause mortality,
but marked lower incidence in non-fatal stroke [74]. In another ran-
domized trial, IDNT study, irbesartan was proved to be better than the
placebo in preventing stroke and MI [75]. In addition, the beneﬁt of
telmisartan was conﬁrmed in TRANSCEND study, in which telmisartan
reduced CV events in high risk — ACEI intolerant patients with the
exception of HF hospitalization [76]. In a recent meta-analysis of 37
RCTs comparing ARB with a placebo or active treatment, ARBs were
associated with statistical reduction in stroke, HF and new-onset diabe-
tes, and in particular they were not inferior to the control group in MI
prevention [77].
The LIFE trial, one of the rare large randomized trials, showed the
better CV outcome of ARB (losartan) than another BP-lowering class
(atenolol) [39]. In the VALUE trial [78] and ONTARGET trial [71], no dif-
ference was found in comparison between CA (amlodipine) and ACEI
(ramipril) in reducing CV risk. In a meta-analysis of three studies
(ALLHAT, ANBP2 and PHYLLIS) [46], although no difference was seen
in total mortality, ARB was inferior to thiazide-type D in incidence of
stroke. Nevertheless, ARBs have been proved to be effective in patients
withHF in Val-HeFT [79], VALIANT [80] and CHARM trials [81]. Obvious-
ly, ARB – amember of RAS blockage group – has been proved to bemore
effective than either the placebo or other antihypertensive drugs in
reducing proteinuria.
3.2. Preferred combination therapy
An important result induced by ALLHAT [41], LIFE [39] and HOT [16]
trials indicated that only a minority of participants obtained target BP
with monotherapy. Despite depending on the severity of hypertension
as well as the comorbid conditions, the BP controlled with single drug
treatment seemed to be successful in Grade 1 (Stage 1) hypertension
only. Moreover, combination treatments are associated with better
efﬁcacy, tolerability, adherence, and timely fashioned BP control. Some
preferred combinations have beenmentioned in somemajor Guidelines
(Table 4).
Among some antihypertensive combination treatments, BB/D was
the most popular one used in randomized trials, but this combination
has not been a favored choice and is also associated with the higher
incidence of new-onset diabetes. Although in comparison with the pla-
cebo in elderly, this combination was linked to better outcomes in CV
events (STOP trial [84]), stroke (Coope trial [85], SHEP trial [32]), it
was not superior to other combinations: ACEI/BB and CA/BB (ALLHAT
trial [41]), CA/D (CONVINCE trial [38]), CA/ACEI (NORDIL [44], INVEST
trial [86]), and was inferior to CA/ACEI (ASCOT trial [87]), ARB/D
(LIFE trial [39]). In addition, only in CAPPP trial in which BB/D was not
signiﬁcantly better than ACEI/D in CV events [42]. With this evidence,BB/D has not been mentioned as the preferred choice in recent
guidelines.
After BB/D, the combination between ACEI and CA was also the
treatment used in trials, with the mechanism that renin–angiotensin-
system blockage can reduce the increasing heart rate and neutralize
the peripheral edema induced by DHP-CA treatment. In Syst-Eur [33]
and Syst-China trials [64] of the elderly, ACEI/CA was associated with
marked reduction in CV events. Despite the fact that no beneﬁt was
seen in comparing between ACEI/CA and with BB/D in NORDIL [44]
and INVEST trials [86], recent results from ASCOT study [87] showed
an impressive beneﬁt in CV event of ACEI/CA in comparison with BB/
D, and data from ACCOMPLISH [88] in high risk population also found
it to be superior to ACEI/D in CV outcome. In contrast, there is little
doubt with this ﬁnding since no previous trial has indicated the superi-
ority of CA to D in hypertensive treatment. However, during the period
of ten years, CA/ACEI has continuously been considered the preferred
therapy in all guidelines. Moreover, since ACEI and ARB were seen to
be similar in all outcomes in the ONTARGET study [73], the extrapolated
ﬁnding could also be applied for ARB/CA.
Another preferred choice of drug combination is D/ACEI. The
PROGRESS [21], large trial in patients with history of stroke or TIA
concluded that this pair of drug treatment had statistical beneﬁt
in reducing the incidence of stroke comparedwith the placebo. Another
trial, ADVANCE, also found that D/ACEI brought about a better
outcomeofmicrovascular andmacrovascular events in diabetic patients
than the placebo [35]. Although no outcome difference was obtained
when D/ACEI was compared with D/BB in CAPPP trial [42], the
data from an important trial in patients older than 80 years old,
HYVET [37], favored D/ACEI to the placebo in signiﬁcantly lowering CV
events.
On the other hand, in hypertensive patients with LVH, D/ARB was
markedly superior to D/BB in stroke outcome [39]. And in the SCOPE
trial, D/ARB was also better than D/placebo in reducing nonfatal stroke
incidence [74].
The combination CA/Dwas a preferred treatment in ESC/ESH Guide-
lines 2013 [4] but was not the one in ASH Guidelines 2010 [83].
Although in the FEVER study [89], CA/D had more beneﬁcial effects on
CV events than the placebo, this combination was not superior to BB/
D in CV events in ELSA [90] and the CONVINCE trial [38].
Finally, the combination of two renin–angiotensin-blockers had
positive effects on proteinuria, however, it was associated with higher
incidence of renal events in the ONTARGET [37] and ALTITUDE trials
[91].3.3. Antihypertensive treatment in compelling indications
3.3.1. Heart failure
In reviewing many guidelines from 2003, Ds, BBs, ACEIs, ARBs and
ALDO ANT have been the vital drugs for heart failure patients, and the
use of ACEIs in all classes of HF is strongly conﬁrmed by most recom-
mendations. Among these classes, BBs, ACEIs, ARBs and ALDO ANT are
associated with persistent survival improvement in HF. Indeed, there
has been no randomized controlled trial in which the effects of BP con-
trol were intended to be evaluated speciﬁcally. The only difference
among the Guidelines mentioned in Table 5 is that CAs were also con-
sidered as initial therapy in HF and hypertension individuals in ACCF/
AHA 2011 Guidelines on Hypertension Management in Elderly [14].
Unlike nifedipine andnon-DHPCA,whichhave negative inotropic activ-
ity and are not recommended to use in heart failure, second-generation
CA (amlodipine and felodipine) has little or no negative inotropic char-
acteristics and was found neither beneﬁcial nor harmful when used in
patients with class II or class III HF [79,92]. However, in general, results
from RCTs of PRAISE [93], PRAISE 2 trials [94] (in amlodipine) and V-
HeFT III trial (in felodipine) [95] showed the lack of beneﬁt of these
CAs in HF.
Table 4
Recommendations for combination therapy.
Sponsoring organizations (year) Referred combinations
JNC 7 (2003) [1] - Thiazide-type diuretics + ACEI, ARB, CA or BB
ESC/ESH Guidelines (2003) [2] - D + BB
- D + ACEI or ARB
- CA (DHP) + BB
- CA + ACEI or ARB
- CA + D
- α-blockers + BB
BHS Guidelines (2004) [11] - D + BB
- D + ACEI or ARB
- CA + BB
- CA + ACEI or ARB
- D + CA + ACEI or ARB (BB) (triple therapy)
NICE Guidelines (2006) [82] - D + ACEI or ARB
- CA + ACEI or ARB
- D + CA + ACEI or ARB
ESC/ESH Guidelines (2007) [9] - Thiazide diuretics + ACEI or ARB
- CA (DHP) + BB
- CA + thiazide diuretics
- CA + ACEI or ARB
AHA & ACC Treatment of Hypertension in the Prevention and
Management of Ischemic Heart Disease (2007) [12]
- Primary prevention: Any combinations between ACEI or ARB, CA, thiazide diuretics
- Secondary prevention: BB + ACEI or ARB (+CA)
(thiazide diuretics: possible, CA: alternative to BB)
ESC/ESH Guidelines for management of hypertension (2009) [10] - Thiazide diuretics + ACEI or ARB
- CA + thiazide diuretics
- CA + ACEI or ARB
- Avoid: BB + D
Canadian Hypertension Education Program — CHEP (2009) [13] - Thiazide diuretics + CA (DHP)
- CA (DHP) + ACEI
- Other combinations (less preferred)
- Not recommend: ACEI + ARB
ASH Guidelines Combination therapy in hypertension (2010) [83] - D + ACEI or ARB
- CA + ACEI or ARB
Canadian Hypertension Education Program — CHEP (2013) [15] - Long acting CA (DHP) + ACEI (most preferred in high risk patients)
- Thiazide diuretics + CA (DHP)
- Other combinations (less preferred)
- Not recommend: ACEI + ARB (except in hypertension with HF refractory to ACEI)
ESC/ESH Guidelines for management of hypertension (2013) [4] - Thiazide diuretics + ACEI or ARB
- CA + thiazide diuretics
- CA + ACEI or ARB
- Not recommend: ACEI + ARB
ACC: American College of Cardiology; ACEI: angiotensin-converting-enzyme inhibitors; AHA: American Heart Association; ARB: angiotensin receptor blockers; BB: beta-blockers; BHS:
British Hypertension Society; CA: calcium antagonist; DHP: dihydropyridine; ESC: European Society of Cardiology; ESH: European Society of Hypertension; HF: Heart failure; JNC 7:
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
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Evidence from many RCTs have conﬁrmed the usage of BB
[57,61,96], ACEI/ARB [97–100], and ALDOANT [101] in patients with re-
cent MI. According to AHA Guidelines 2007 [12], long-acting DHP CA
can be usedwhen BB is contraindicated or inadequate to control angina,
or used as adjunct therapy for BP control. (Table 6)Table 5
Antihypertensive drugs in hypertension and heart failure.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + + + + +
ESC/ESH (2003) + + + + +
BHS (2004)–(2006) + + + + +
ESC/ESH (2007) + + + + +
ESC/ESH (2009) + + + + +
CHEP (2009–2013) + + + + +
ACCF/AHA (2011) + + + + + +
ESC/ESH (2013) + + + + +3.3.3. Coronary artery disease or high cardiovascular disease risk
In patients with chronic coronary artery disease or high risk of CVD,
thiazide diuretic treatment proved to be highly effective in reducing BP
and preventing CV outcomes [32,41,102]. Moreover, randomized trials
also found beneﬁts of ACEI therapy in this type of patient, for example
HOPE trial [23], Lee et al. meta-analysis [103], SAVE [104] and EUROPA
trials [28]. On the other hand, CAs were conﬁrmed not to be inferior to
thiazide diuretics or ACEIs in primary prevention of CV events in the
ALLHAT trial [41], and CA (verapamil) was equivalent in CV outcomes
compared with D or BB in high risk patients in the CONVINCE [38] or
INVEST trials [86], respectively. Another similar result was gained
from the NORDIL trial [44] in which CA (diltiazem) compared with the
combination of D/BB had no statistical difference in CVD incidence. In
addition, ARBs had less evidence than other classes of drugs in high
risk patients, although the VALUE study (losartan versus amlodipine)
[78] and the VALIANT (valsartan versus captopril) [80] trials in CAD or
high CAD risk patients found the similar effects of ARBs in CVD primaryprevention or CV events. Finally, BBs have always been the ﬁrst choice
for hypertensive patients with CAD through many Guidelines of AHA
[12,14] and ECS/ESH [2,4,9,10] with evidence mentioned above. (Table
7).
3.3.4. Diabetes mellitus
In 2003, JNC 7 [1] demonstrated that it was difﬁcult to ﬁnd which
antihypertensive agent was the best choice in diabetes since most of di-
abetic hypertensive needed at least two drugs for BP control.
Renin–angiotensin–aldosterone-system blockers have been found
to have more persistent beneﬁts in diabetes patients with or without
nephropathy among antihypertensive treatments. Despite results from
the ALLHAT trial (with 36% diabetic participants) that CA, ACEI and
Table 6
Antihypertensive drugs in post MI with hypertension.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + + +
ESC/ESH (2003) + + +
BHS (2004)–(2006) + + + +
ESC/ESH (2007) + + + +
AHA (2007) + + + +
ESC/ESH (2009) + + + +
CHEP (2009–2013) + + + +
ACCF/AHA (2011) + + + +
ESC/ESH (2013) + + + +
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death and non-fatal MI [41], many trials including UKPDS (ACEI versus
BB) [17], CAPPP trial (ACEI versus D/BB) [42], Estacio study (ACEI versus
CA) [105], LIFE (ARB versus BB) [39] and INT (ARB versus CA) [106], all
demonstrated that ACEIs/ARBs were superior to other drugs in diabetic
related endpoints of microvascular disease, stroke, retinopathy deterio-
ration (UKPDS) [17], in major CV events (CAPPP [42], Estacio [105] and
LIFE trials [39]), in reducing incidence of new proteinuria (LIFE trial
[39]) and renal dysfunction or failure (INT study [106]). Combination
therapy of both ACEI and ARB, however, was related to a higher inci-
dence of renal adverse effects in the ONTARGET [73] and ALTITUDE tri-
als [91]. In spite of data that the presence of microalbuminuria has been
considered both early predictor of renal damage and high CV risk, the
ADVANCE [35] and ROADMAP [107] trials, both cannot ﬁnd the linear
relationship between reducing proteinuria related to treatment and
lowering hard CV outcomes.
Thiazide diuretics are also mentioned in hypertensive treatment of
diabetes patients based on results from the ALLHAT trials in which
chlorthalidone was superior to amlodipine and lisinopril in preventing
new-onset HF [41].
Moreover, although there was little evidence approving the use of
BB in patients with no history of CAD since most of the data resulted
from trials on old-BB (atenolol), some studies in diabetic individuals
demonstrated that a new BB, carvedilol, improved survival in patients
with HF and had consistent advantages compared with metoprolol or
atenolol [60,108]. In the GEMINI trial, carvedilol was related to no
changes in HbA1c, increasing insulin sensitivity and worsening glyce-
mic control at the less extent compared with metoprolol [60].
On the other hand, another class of antihypertensive agent, CAs, has
also been seen in some Guidelines of diabetic patients. HOT [16] and
Syst-Eur [33] study conﬁrmed no evidence of deleterious effect from a
long-acting DHP in diabetic participants. This ﬁnding was supported by
ALLHAT trial [41]. A meta-analysis of 14 studies [109] also reconﬁrmed
that CA is safe and effective in reducing most types of CV morbidity and
mortality in hypertensive diabetic patients, although less effectiveness
was noted in reduction of HF risk than renin–angiotensin-system
blockers.
Finally, ameta-analysis of 27 studies in 2005 showed that all classes of
antihypertensive drugs (ACEI, ARB, CA, BB and D) were all useful inTable 7
Antihypertensive drugs in hypertension and CAD or high risk CVD.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + + + +
ESC/ESH (2003) + + +
BHS (2004)–(2006) + + +
ESC/ESH (2007) + + +
AHA (2007) + + + + +
ESC/ESH (2009) + + +
CHEP (2009–2013) + + +
ACCF/AHA (2011) + + + +
ESC/ESH (2013) + + +reducing major CV events in diabetes patients [110]. However, based on
solid evidence, it is reasonable to combine one of the renin–angioten-
sin-system blockers with other agents in hypertensive diabetic patients.
Recently, there is a trend of CA/ACEI combination by data from the
ACCOMPLISH trial in which benazepril/amlodipine had more positive
results than benazepril/hydrochlorothiazide in primary endpoints of
CVD mortality, non-fatal MI, non-fatal stroke, hospitalization for angina,
resuscitation after sudden cardiac death or coronary revascularization
[88]. (Table 8)
3.3.5. Chronic kidney disease
In allmajorGuidelines from2003 to 2013, ACEIs andARBs have been
the cornerstone in hypertensive chronic kidney disease patients. As
evidence for renin–angiotensin-system blockers in diabetic nephropa-
thy is mentioned above, strong data from RCTs also demonstrated the
role of ACEIs and ARBs in non-diabetic hypertensive individuals. Some
RCTs consistently conﬁrmed the role of ACEIs or ARBs in chronic kidney
disease. In comparison with the placebo, ACEIs or ARBs had better ef-
fects on reducing urinary albumin excretion [111,112]. In AASK [113],
ACEI (ramipril) was better than CA (amlodipine) in slowing the decline
of GFR. Moreover, a meta-analysis of 11 trials showed the higher effec-
tiveness in the regimen containing ACEI than the one without it [26]. In
another meta-analysis in 2008 of 49 RCTs in patients with and without
diabetics, ACEI and ARB had equivalent effect in lowering proteinuria,
but also they were also superior to CA in this outcome [114]. (Table 9)
3.3.6. Recurrent stroke prevention
During the period of ten years, Ds and ACEIs have been considered
the main hypertensive treatment in patients with previous stroke or
TIA. The evidence of Ds came from some RCTs (ALLHAT [41], PROGRESS
[21] and PATS trials [22]), and data from PROGRESS [21] and PATS trials
[22], which showed beneﬁt of Ds in secondary prevention of stroke,
were seen in both hypertensive and non-hypertensive participants. In
addition, in the PROGRESS (indapamide/peridopril versus placebo)
[21], HOPE (ramipril versus placebo) [23], subgroup analysis of SCOPE
(candesartan versus placebo) [74] or the LIFE study (losartan versus
atenolol) [39], signiﬁcant beneﬁt in preventing stroke recurrence was
induced by ACEI or ARB.
Although data was obtained from many previous studies in stroke
prevention of CA [57,110,115] until recently, CAs have been recom-
mended to use in cerebrovascular patients in ACCF/AHA Guidelines
2011 and ESC/ESH Guidelines 2013. (Table 10)
4. Conclusion
Antihypertensive treatment approach has had tremendous changes
by novel data from RCTs and meta-analyses. In BP classiﬁcation, the
unity has not been gained since ESC/ESH and BHS did not approve the
term “prehypertension”, which was recommended by JNC 7. In high nor-
mal BP range, which can be considered a subclass of prehypertension,
recently, Guidelines from Europe share the same view with that JNC 7
and CHEP that initial pharmacology therapy is not beneﬁcial.
Moreover, by reviewing data from randomized trials, beneﬁt from
strict BP control in diabetes, CKD, other CVD as well as in elderly wasTable 8
Antihypertensive drugs in hypertension and diabetes mellitus.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + + + + +
ESC/ESH (2003) + +
BHS (2004)–(2006) + +
ESC/ESH (2007) + + + + +
ESC/ESH (2009) + + + +
CHEP (2009–2013) + + + +
ACCF/AHA (2011) + + + + +
ESC/ESH (2013) + + + + +
Table 10
Antihypertensive drugs in hypertension and secondary stroke prevention.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + +
ESC/ESH (2003) + +
BHS (2004)–(2006) + +
ESC/ESH (2007) + + +
ESC/ESH (2009) + + +
CHEP (2009–2013) + +
ACCF/AHA (2011) + + + +
ESC/ESH (2013) + + + + +
Table 9
Antihypertensive drugs in hypertension and CKD.
Organization (year) D BB ACEI ARB CA ALDO ANT
JNC 7 (2003) + +
ESC/ESH (2003) + +
BHS (2004)–(2006) + +
ESC/ESH (2007) + +
ESC/ESH (2009) + +
CHEP (2009–2013) + +
ACCF/AHA (2011) + +
ESC/ESH (2013) + +
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85 mm Hg for diabetics, below 140/90 for CKD or CVD patients and
140–150/90 mm Hg in elderly.
The question of which antihypertensive drug is favorable in all cases
still has not been resolved, but data frommany RCTs andmeta-analyses
failed to show positive effects of BBs on uncomplicated hypertension. In
addition, achieving target BP in hypertensive, especially in patients with
compelling indications, was nearly impossible by monotherapy. In
many new trials concerning the best combination, however, conﬂicting
data was gained. Amongmany combinations, Ds/BBs, which had higher
incidence of new-onset diabetes mellitus, and CAs/BBs, which had less
beneﬁt than others, are no longer favored in hypertensive treatment.
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